Other languages Passage Bio, Inc.

Equities

PASG

US7027121000

Market Closed - Nasdaq Other stock markets 01:30:00 27/04/2024 am IST			5-day change	1st Jan Change
1.32 ^USD	+8.20%		+14.78%	+30.69%

04/03	Passage Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
04/03	Passage Bio, Inc. Appoints Kathleen Borthwick as Chief Financial Officer	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Passage Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04/03
Passage Bio Says Data From Phase 1/2 Trial of Dementia Therapy Exceeded Expectations	21/12
Passage Bio, Inc. Announces Promising Initial Data from Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities	20/12
Passage Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Passage Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	07/23/07
Passage Bio, Inc. Announces New Interim Safety, Biomarker, and Survival Data from Cohorts 1-4 in Imagine-1 Clinical Study	07/23/07
Passage Bio, Inc. Announces Board and Committee Changes	31/23/31
Passage Bio, Inc. Announces Executive Changes	20/23/20
Passage Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/23/11
Passage Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	06/23/06
Passage Bio, Inc. Presents Additional Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023	24/23/24
Passage Bio Reports 'Positive' Interim Results of Gene Therapy Trial for GM1 Gangliosidosis in Children; Shares Rise	15/22/15
Passage Bio, Inc. Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study	14/22/14
Passage Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/22/10
Passage Bio, Inc. Announces Resignation of Maxine Gowen as Interim Executive Chairwoman	10/22/10
Passage Bio, Inc. Announces Chief Executive Officer Changes	10/22/10
Passage Bio, Inc. Announces Executive Changes	10/22/10
Passage Bio Doses First Patient in Global Clinical Trial of PBFT02 Gene Therapy for Frontotemporal Dementia with Granulin Mutations	11/22/11
Passage Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	04/22/04
Passage Bio, Inc. Appoints Michael Kamarck to Board of Directors	06/22/06

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Passage Bio, Inc.

Equities

PASG

US7027121000

Other languages

Filters